Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type b

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 11, 2004, Pages 727-734

  Ek, Torben ^a,b   Mellander, Lotta ^a   Hahn Zoric, Mirjana ^a   Abrahamsson, Jonas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Childhood acute lymphoblastic leukemia; Diphtheria; Haemophilus influenzae type b; Memory B cells; Tetanus

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIPHTHERIA TOXOID; DOXORUBICIN; DUPLEX; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TETANUS TOXOID; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL INFECTION; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INTENSIVE CARE; MALE; PEDIATRICS; PRIORITY JOURNAL; STANDARDIZATION; TETANUS; VACCINATION;

ADOLESCENT; ANTIBODIES; ANTIBODY FORMATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; TETANUS TOXOID; TIME FACTORS;

EID: 9644275427     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200411000-00008     Document Type: Article

References (31)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia: current status and future perspectives. Lancet Oncol. 2001;2: 597-607.
2. Lehrnbecher T, Foster C, Vazquez N, et al. Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol. 1997;19:399-417.
3. Mustafa MM, Buchanan GR, Winick NJ, et al. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol. 1998;20:451-457.
4. Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992;69:1481-1486.
5. Abrahamsson J, Marky I, Mellander L. Immunoglobulin levels and lymphocyte response to mitogenic stimulation in children with malignant disease during treatment and follow-up. Acta Paediatr. 1995;84:177-182.
6. Abrahamsson J, Mellander L. Bone marrow immunoglobulin-secreting cells are not reduced in children with leukaemia as compared to children with solid tumours. Acta Paediatr. 1997;86:165-169.
7. Caver TE, Slobod KS, Flynn PM, et al. Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia. Leukemia. 1998;12:619-622.
8. Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11:281-292.
9. Smith S, Schiffman G, Karayalcin G, et al. Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster therapy. J Pediatr. 1995;127:68-75.
10. Nilsson A, De Milito A, Engstrom P, et al. Current chemotherapy protocols for childhood acute lymphoblastic leukemia induce loss of humoral immunity to viral vaccination antigens. Pediatrics. 2002; 109:e91.
11. Ljungman P, Cordonnier C, de Bock R, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995; 15:455-460.
12. Mahajan A, English MW, Jenney ME, et al. Survey of immunisation practices in the United Kingdom during and following completion of anti-cancer chemotherapy in children. Med Pediatr Oncol. 2003;40:270-271.
13. van der Does-van den Berg A, Hermans J, Nagel J, et al. Immunity to diphtheria, pertussis, tetanus, and poliomyelitis in children with acute lymphocytic leukemia after cessation of chemotherapy. Pediatrics. 1981; 67:222-229.
14. Kung FH, Orgel HA, Wallace WW, et al. Antibody production following immunization with diphtheria and tetanus toxoids in children receiving chemotherapy during remission of malignant disease. Pediatrics. 1984; 74:86-89.
15. Ridgway D, Wolff LJ, Deforest A. Immunization response varies with intensity of acute lymphoblastic leukemia therapy. Am J Dis Child. 1991; 145:887-891.
16. von der Hardt K, Jungert J, Beck JD, et al. Humoral immunity against diphtheria, tetanus and poliomyelitis after antineoplastic therapy in children and adolescents: a retrospective analysis. Vaccine. 2000;18: 2999-3004.
17. Feldman S, Gigliotti F, Shenep JL, et al. Risk of Haemophilus influenzae type b disease in children with cancer and response of immunocompromised leukemic children to a conjugate vaccine. J Infect Dis. 1990; 161:926-931.
18. Lakew M, Nordstrom I, Czerkinsky C, et al. Combined immunomagnetic cell sorting and ELISPOT assay for the phenotypic characterization of specific antibody-forming cells. J Immunol Methods. 1997;203:193-198.
19. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr. 1998;87:1151-1161.
20. Saarinen-Pihkala UM, Gustafsson G, Carlsen N, et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer. 2004;42:8-23.
21. Galazka AM. The Immunological Basis for Immunization Series (2): Diphtheria. Expanded Programme on Immunization. Geneva: WHO, 1993.
22. Galazka AM. The Immunological Basis for Immunization Series (3): Tetanus. Expanded Programme on Immunization. Geneva: WHO, 1993.
23. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001;20:63-75.
24. Tarkowski A, Lue C, Moldoveanu Z, et al. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol. 1990;144:3770-3778.
25. Reinhardt D, Houliara K, Pekrun A, et al. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis. 2003;35:851-857.
26. Christenson B, Bottiger M. Immunity and immunization of children against tetanus in Sweden. Scand J Infect Dis. 1991;23:643-647.
27. Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis. 2000;31:973-980.
28. Lange B, Jakacki R, Nasab AH, et al. Immunization of leukemic children with Haemophilus conjugate vaccine. Pediatr Infect Dis J. 1989;8:883-884.
29. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis. 1998;177:1112-1115.
30. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272:54-60.
31. Traggiai E, Puzone R, Lanzavecchia A. Antigen-dependent and -independent mechanisms that sustain serum antibody levels. Vaccine. 2003;21(Suppl 2):S35-S37.